The third arm of the phase-II ILUSTRO trial covered three CLDN18.2 high or intermediate (CLDN18 staining is moderate to strong in 50%–75% of the tumor cells’ membranes) patient groups, who were treated with third-line or later zolbetuximab and pembrolizumab [133]. Here, CLDN18 is linked to neoplasm.